Prosecution Insights
Last updated: November 06, 2026

Regeneron Pharmaceuticals Inc.

Technology area: Biotechnology & Pharmaceuticals

138 pending office actions • 52 art units • 110 examiners • 1 of 138 (1%) have an AI response strategy ready • 161 patents granted in the last 365 days

Analysis

Regeneron Pharmaceuticals Inc. has 143 pending office actions in Biotechnology & Pharmaceuticals. The matters span 114 distinct examiners and 53 distinct art units, reflecting a substantial portfolio distributed across many examination assignments.

XU, XIAOYUN is the busiest examiner, with 4 pending matters. The examiner relationship provides one point for focused coordination, but the broader docket requires systematic management across art units and technical programs. Counsel may benefit from centralized review of recurring biotechnology claim and evidence issues, paired with examiner-specific response planning.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

138
Total Pending OAs
99
Non-Final OAs
33
Final Rejections
6
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 26 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

10
Overdue
1
Due this week
5
Due this month
7
Due in next 60 days
3
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 26 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (10)Due ≤ 7 days (1)Due ≤ 30 days (5)Due ≤ 60 days (7)Due later (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

59
Hard (43%)
46
Medium (33%)
28
Easy (20%)
5
Unknown (4%)

Rejection Statute Mix

BucketCases
§101 only1 (1%)
§101 + other22 (16%)
§103 only24 (17%)
§102 only2 (1%)
§112 only26 (19%)
Double-patenting only2 (1%)
Double-patenting + other20 (14%)
Multi-statute (no §101)36 (26%)
No statute on record5 (4%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

125
Life Sciences
91% of docket
1
Information Tech
1% of docket
0
Communications
0% of docket
2
Semiconductors
1% of docket
8
Mechanical / Eng
6% of docket
2
Business / Other
1% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

1,380 h
Manual time on pending OAs
276 h
Time saved (low, 20%)
483 h
Time saved (mid, 35%)
12.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
XU, XIAOYUN 4 59.9% +31.5%
WILSON, MICHAEL C 4 41.5% +17.8%
LI, RUIXIANG 3 59.5% +18.7%
KIM, YUNSOO 3 66.1% +34.0%
HOWARD, ZACHARY C 3 64.0% +37.8%
BENAVIDES, JENNIFER ANN 3 50.8% +48.2%
DONOGHUE, BRITTNEY ERIN 3 59.0% +47.6%
STONEBRAKER, ALYSSA RAE 3 59.5% +49.6%
WEHBE, ANNE MARIE SABRINA 2 57.3% +43.3%
HAQ, SHAFIQUL 2 64.9% +55.3%

Hard Cases (59)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18130980 COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST HOWARD, ZACHARY C 127d overdue
18336148 SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE MEDWAY, SCOTT J 25d overdue
17954999 ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS EVANS, CHRISTOPHER RYAN 4d overdue
17041252 GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF WILSON, MICHAEL C 4d overdue
17433887 ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS LEONARD, ARTHUR S 6d
17885805 MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC WHITE, ASHLEY TAYLOR 13d
17204253 NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN NGUYEN, NAM P 26d
18452452 INTERFERON RECEPTOR AGONISTS AND USES THEREOF JOHNSON, TIRONE DEREK 34d

Interview Candidates (30)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18130980 COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST HOWARD, ZACHARY C 127d overdue
17887565 IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF DONOGHUE, BRITTNEY ERIN 15d overdue
17041252 GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF WILSON, MICHAEL C 4d overdue
19248893 METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY KIM, YUNSOO 8d
19333264 Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies LI, RUIXIANG 43d
17870368 NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY XU, XIAOYUN 55d
18999448 COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX WEHBE, ANNE MARIE SABRINA —
18817850 METHODS FOR CHARACTERIZING A PROTEIN OF INTEREST XU, XIAOYUN —

Top Art Units

Art UnitApps
1674 9
1642 9
1641 7
1675 7
1678 6
1638 6
1634 5
1647 5
1797 4
1631 4

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19333578 DEVICES AND METHODS FOR OVERFILLING DRUG CONTAINERS SHRIEVES, STEPHANIE ALEXANDRA 3753 DP Non-Final OA — Pending Sep 19, 2025
19333264 Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies LI, RUIXIANG 1674 §103 Non-Final OA 43d Pending Sep 18, 2025
19290943 BRACKETING DEVICE FOR MANUFACTURING PARTS CLEANER AND METHODS THEREFOR EPPS, TODD MICHAEL 3632 Other Non-Final OA — Pending Aug 05, 2025
19248893 METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY KIM, YUNSOO 1641 §112DP Non-Final OA 8d Pending Jun 25, 2025
19057507 MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS BALL, JOHN C 1795 §103§112Other Non-Final OA — Pending Feb 19, 2025
19024513 VEGF-TRAP PROTEIN VARIANTS AND ANALYSIS THEREOF SUN, CAITLYN MINGYUN 1795 §103 Non-Final OA — Pending Jan 16, 2025
18999448 COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX WEHBE, ANNE MARIE SABRINA 1634 §103§112DP Non-Final OA — Pending Dec 23, 2024
18942224 ASPARAGINE FEED STRATEGIES TO IMPROVE CELL CULTURE PERFORMANCE AND MITIGATE ASPARAGINE SEQUENCE VARIANTS SINGH, SATYENDRA K 1657 §103 Non-Final OA — Pending Nov 08, 2024
18918283 RAPID PURIFICATION OF MONOCLONAL ANTIBODY FROM IN-PROCESS UPSTREAM CELL CULTURE MATERIAL KNIGHT, TERESA E 1634 §102§103 Non-Final OA — Pending Oct 17, 2024
18884527 Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors MEYERING, SHABANA SHABBEER 1635 §101§102§103§112 Non-Final OA — Pending Sep 13, 2024
18830643 ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF BOESEN, AGNIESZKA 1672 §112 Non-Final OA — Pending Sep 11, 2024
18817850 METHODS FOR CHARACTERIZING A PROTEIN OF INTEREST XU, XIAOYUN 1797 §102§103 Non-Final OA — Pending Aug 28, 2024
18798198 Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors KONOPKA, CATHERINE ANNE 1635 §103§112DP Non-Final OA — Pending Aug 08, 2024
18786335 METHODOLOGY TO CHARACTERIZE EMPTY-FULL RATIO IN CRUDE AAV SAMPLES GILL, RACHEL B 1671 §102§103§112 Non-Final OA — Pending Jul 26, 2024
18785975 HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES RICCI, CRAIG D 1611 §102§112Other Non-Final OA — Pending Jul 26, 2024
18777757 SYSTEMS AND METHODS FOR MOTOR ASSESSMENT EDWARDS, ETHAN WESLEY 2857 §101§103 Non-Final OA — Pending Jul 19, 2024
18776820 METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST HOWARD, ZACHARY C 1674 Other Non-Final OA — Pending Jul 18, 2024
18763265 METHODS FOR MITIGATING DRUG TARGET INTERFERENCE IN AN ANTI-DRUG ANTIBODY (ADA) IMMUNOASSAY HAQ, SHAFIQUL 1678 §103§112DP Non-Final OA — Pending Jul 03, 2024
18763490 METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS DACE DENITO, ALEXANDRA GERALDINE 1636 §103 Non-Final OA — Pending Jul 03, 2024
18721743 NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI GRABER, JAMES J 1631 §101§102§103§112DP Non-Final OA — Pending Jun 19, 2024
18737782 Anti-Trkb Monoclonal Antibodies And Methods Of Use LI, RUIXIANG 1674 §112 Non-Final OA — Pending Jun 07, 2024
18734482 LOW AFFINITY FcyR DEFICIENT MICE WILSON, MICHAEL C 1638 §112Other Non-Final OA — Pending Jun 05, 2024
18674399 METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS HOWARD, ZACHARY C 1674 §112Other Non-Final OA — Pending May 24, 2024
18670684 Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof BURKHART, MICHAEL D 1638 — Non-Final OA — Pending May 21, 2024
18670301 STEROIDS AND ANTIBODY-CONJUGATES THEREOF LU, CHENG 1642 §103§112Other Non-Final OA — Pending May 21, 2024
18670314 STEROIDS AND ANTIBODY-CONJUGATES THEREOF LU, CHENG 1642 §103DP Non-Final OA — Pending May 21, 2024
18669172 Anti-CTLA-4 Antibodies and Uses Thereof ROONEY, NORA MAUREEN 1641 §112DP Non-Final OA — Pending May 20, 2024
18710939 METHODS AND COMPOSITIONS FOR REDUCING CENTRALIZED PAIN FAUST, AMBER KATHLEEN 1643 §102§103§112Other Non-Final OA — Pending May 16, 2024
18659538 SYSTEMS AND METHODS FOR REDUCING SAMPLE SIZES ERICKSON, BENNETT S 3683 §101§103 Non-Final OA — Pending May 09, 2024
18707263 NON-HUMAN ANIMALS COMPRISING A MODIFIED CACNG1 LOCUS MIANO, JOSEPH PAUL 1631 §101§102§103 Non-Final OA — Pending May 03, 2024
18647109 METHODS FOR CHARACTERIZING LOW-ABUNDANCE HOST CELL PROTEINS CHIN, CHRISTOPHER L 1677 §101 Non-Final OA — Pending Apr 26, 2024
18645694 METHODS FOR SELECTING EXCIPIENTS AND FOR PREPARING HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS AND OTHER FORMULATIONS COMPRISING PROTEINS SAOUD, CHRISTINE J 1645 §102§103§112 Non-Final OA — Pending Apr 25, 2024
18642721 ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS BENAVIDES, JENNIFER ANN 1675 §112 Final Rejection — Pending Apr 22, 2024
18637055 CONCENTRATION-DEPENDENT SELF-INTERACTION ASSAY NGUYEN, NAM P 1678 §102§103§112 Non-Final OA — Pending Apr 16, 2024
18634633 SYSTEMS, METHODS, AND APPARATUSES FOR IMPROVED INSTRUMENT MONITORING AND ANALYTICS MINCEY, JERMAINE A 2159 §101§102§103 Non-Final OA — Pending Apr 12, 2024
18699454 STEREOCILIN PROMOTERS AND USES THEREOF MOLOYE, TITILAYO 1632 — Non-Final OA — Pending Apr 08, 2024
18612039 METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST DONOGHUE, BRITTNEY ERIN — §102§112Other Non-Final OA — Pending Mar 21, 2024
18610188 COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMA CELL ABALATION FOR TREATING ALLERGY CHANDRA, GYAN 1674 §112 Non-Final OA — Pending Mar 19, 2024
18604573 METHODS FOR OBTAINING ANTIBODY MOLECULES WITH HIGH AFFINITY MARCSISIN, ELLEN JEAN 1677 §103§112 Non-Final OA — Pending Mar 14, 2024
18603862 SYSTEMS AND METHODS FOR IDENTIFYING EVENTS IN SUPPLY CHAIN PROCESSES GARCIA-GUERRA, DARLENE 3625 §101§103 Final Rejection — Pending Mar 13, 2024
18592388 ANTI-FEL D1 ANTIBODY FORMULATIONS KIM, YUNSOO 1641 §103DP Non-Final OA — Pending Feb 29, 2024
18589384 MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF METCALF, MATTHEW CURRAN 1647 §102§103DP Non-Final OA — Pending Feb 27, 2024
18582159 Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) KAPUSHOC, STEPHEN THOMAS 1683 §112DP Non-Final OA — Pending Feb 20, 2024
18444273 INDUCED NK CELLS RESPONSIVE TO CD3/TAA BISPECIFIC ANTIBODIES LANDSMAN, ROBERT S 1647 §103§112 Non-Final OA — Pending Feb 16, 2024
18436306 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF GONZALEZ, LUISALBERTO 1624 §112 Non-Final OA — Pending Feb 08, 2024
18432780 Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies LI, RUIXIANG 1674 §112Other Non-Final OA — Pending Feb 05, 2024
18429572 ASYMMETRICAL FLOW FIELD-FLOW FRACTIONATION WITH MASS SPECTROMETRY FOR BIOMACROMOLECULE ANALYSIS XU, XIAOYUN 1797 §102§103§112 Non-Final OA — Pending Feb 01, 2024
18421538 CHARACTERIZATION OF SERINE-LYSINE CROSS-LINK IN ANTIBODY HIGH MOLECULAR WEIGHT SPECIES COLE, HOUSTON DAVID 1758 §101§102§103§112 Non-Final OA — Pending Jan 24, 2024
18572930 ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOF HADDAD, MAHER M 1641 §103Other Final Rejection — Pending Dec 21, 2023
18543857 HUMAN LAMBDA LIGHT CHAIN MICE WILSON, MICHAEL C 1638 §112DP Non-Final OA — Pending Dec 18, 2023

View all 138 →

Managing Regeneron Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Regeneron Pharmaceuticals Inc. have?

Regeneron Pharmaceuticals Inc. has 138 pending office actions as of November 2026, spread across 52 art units and 110 examiners.

Which USPTO examiner handles the most Regeneron Pharmaceuticals Inc. applications?

Xiaoyun Xu has the most, with 4 of Regeneron Pharmaceuticals Inc.'s pending office actions.

What technology area are Regeneron Pharmaceuticals Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month